GARASONE OPHTHALMIC AND OTIC SOLUTION 3 MG — DIN 00682217
GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG · MERCK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is GARASONE OPHTHALMIC AND OTIC SOLUTION?
GARASONE OPHTHALMIC AND OTIC SOLUTION 3 MG contains GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 00682217, held by MERCK CANADA INC, supplied as SOLUTION for OPHTHALMIC ; OTIC administration. Health Canada currently lists it as cancelled post market, status dated 01-Apr-2014. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is GARASONE OPHTHALMIC AND OTIC SOLUTION used for?
GARASONE Ophthalmic/Otic Solution and GARASONE Ophthalmic Ointment are indicated for ocular inflammation when concurrent use of an antimicrobial is judged necessary, e.g. staphylococcal blepharoconjunctivitis. GARASONE is indicated for the treatment of non-purulent bacterial infections of the anterior segment of the eye due to organisms sensitive to the antibiotic and when the anti-inflammatory action of betamethasone sodium phosphate is indicated, as in allergic vernal and phlyctenular conjunctivitis; non-purulent blepharitis; interstitial sclerosing post- operative keratitis; superficial chemical and thermal burns of the cornea. GARASONE Ophthalmic/Otic Solution may also be used for the treatment of lesions in the external ear canal, such as acute otitis externa, eczematoid-dermatitis, seborrheic dermatitis and contact dermatitis secondarily infected with susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Betamethasone And Antiinfectives cost around the world?
Betamethasone And Antiinfectives is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 24 | 43 | ZAR███.██ |
| Morocco | PPV (public price) | 10 | 20 | MAD███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Bahrain | retail (max) | 5 | 6 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
81 pack listings across 51 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Betamethasone And Antiinfectives pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Betamethasone And Antiinfectives in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Betamethasone And Antiinfectives, across 5 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| DOMINION PHARMACAL | 1 | 0 | DOM-GENTAMICIN-BETAMETHASONE | No marketed DIN |
| MERCK CANADA INC | 1 | 0 | GARASONE OPHTHALMIC AND OTIC SOLUTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-GENTAMICIN-BETAMETHASONE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | SANDOZ PENTASONE | No marketed DIN |
| STERIMAX INC | 1 | 0 | BETAMYCIN OPHTHALMIC/OTIC SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC ; OTIC |
| Pack configuration (monograph) | GARASONE Ophthalmic /Otic Solution - 7.5 mL dropper bottle, GARASONE Ophthalmic Ointment - 3.5 gram tube |
| Storage | Store between 15 and 30°C, away from light. Store between 15 and 30°C. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Betamethasone And Antiinfectives |
|---|---|
| ATC code | S03CA06 |
| AHFS class | 52:08.08 ; 52:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00682217 |
|---|---|
| DIN (unpadded, as printed on some documents) | 682217 |
| Brand name | GARASONE OPHTHALMIC AND OTIC SOLUTION |
| Generic / active ingredient | GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG |
| Market authorization holder | MERCK CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | S03CA06 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S03CA |
| Current status | CANCELLED POST MARKET |
| Status date | 01-Apr-2014 |
| Original market date | 1987-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Ophthalmic: 2 drops 3-4 times daily (solution) or thin film 3-4 times daily (ointment). Otic: 3-4 drops 3 times daily. Reassess otic use after 5-7 days.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to components; viral (herpes simplex), mycobacterial, or fungal infections of the eye/ear; perforated tympanic membranes (otic use); after corneal foreign body removal.
Warnings and precautions
Prolonged use may increase intraocular pressure or cause cataracts. Potential eighth cranial nerve toxicity (ototoxicity) with otic use. Do not inject solution subconjunctivally.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BETAMYCIN OPHTHALMIC/OTIC SOLUTION | 3 MG | SOLUTION | STERIMAX INC | CANCELLED PRE MARKET | 02247446 |
| DOM-GENTAMICIN-BETAMETHASONE | 1 MG | LIQUID | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02238818 |
| PMS-GENTAMICIN-BETAMETHASONE | 3 MG | LIQUID | PHARMASCIENCE INC | CANCELLED PRE MARKET | 02238819 |
| SANDOZ PENTASONE | 3 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02244999 |
2 · Same class — other molecules in ATC S03CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dexamethasone And Antiinfectives | NEODECADRON EYE EAR SOLN 0.1% · SANDOZ OPTICORT · SOFRACORT · SOFRACORT EAR/EYE OINTMENT · +3 more | 8 | 1 | Yes |
| Hydrocortisone And Antiinfectives | CORTISPORIN · NEO-CORTEF EYE EAR DROPS STERILE SUSPENSION · PENTAMYCETIN/HC · SOPAMYCETIN/HC OINTMENT · +1 more | 6 | 0 | Not in Canada |
| Betamethasone And Antiinfectives | BETAMYCIN OPHTHALMIC/OTIC SOLUTION · DOM-GENTAMICIN-BETAMETHASONE · GARASONE OPHTHALMIC AND OTIC SOLUTION · PMS-GENTAMICIN-BETAMETHASONE · +1 more | 5 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is GARASONE OPHTHALMIC AND OTIC SOLUTION called?
The same molecule, Betamethasone And Antiinfectives, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Betnovate | Latin | South Africa |
| Diprosone | Latin | Morocco, South Africa |
| CELESTENE | Latin | Morocco |
| Lenovate | Latin | South Africa |
| Persivate | Latin | South Africa |
| Betanoid | Latin | South Africa |
| Topivate Cream | Latin | South Africa |
| BETADERM | Latin | Bahrain |
| BETNEVAL | Latin | Morocco |
| Betnovate C | Latin | South Africa |
| Betnovate N | Latin | South Africa |
| Celestone | Latin | South Africa |
| Repivate | Latin | South Africa |
| SKINOSONE | Latin | Morocco |
| Betadexamine | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.